Pharsight

Drugs that contain Inclisiran Sodium

1. Leqvio patents expiration

LEQVIO's oppositions filed in EPO
LEQVIO Litigations
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9074213 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Mar, 2022

(2 years ago)

US8546143 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Apr, 2022

(1 year, 11 months ago)

US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(1 year, 1 month ago)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(5 months ago)

US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(3 months ago)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(a month ago)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(a month ago)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(a month ago)

US11530408 NOVARTIS Therapeutic compositions
May, 2024

(a month from now)

US8809292 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
May, 2027

(3 years from now)

US10131907 NOVARTIS Glycoconjugates of RNA interference agents
Aug, 2028

(4 years from now)

US9370582 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8828956 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US10806791 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8106022 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(5 years from now)

US10125369 NOVARTIS PCSK9 iRNA compositions and methods of use thereof
Aug, 2034

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10590418 NOVARTIS Methods and compositions for RNAi mediated inhibition of gene expression in mammals
Jul, 2022

(1 year, 8 months ago)

US10266825 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(5 months ago)

US8222222 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
Dec, 2027

(3 years from now)

US10851377 NOVARTIS Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2026

NCE-1 date: 22 December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

LEQVIO family patents

Family Patents